Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 13th World Congress on Infection Prevention and Control Rome, Italy.

Day 1 :

Keynote Forum

Waleed A. Mazi

Regional Directorate for Infection Prevention and Control
Directorate of Health Affairs, Taif
Kingdom of Saudi Arabia

Keynote: Strategies in developing an Effective Infection Prevention and Control Program

Time : 10:00AM- 10:40 AM

OMICS International Infection Prevention 2017 International Conference Keynote Speaker Waleed A. Mazi photo
Biography:

Waleed A. Mazi is a Regional Director for Infection Prevention and Control, Taif – Saudi Arabia, and also worked in Philosophy of Medical Science, Clinical Microbiology in Sweden. He also Became Infection Prevention and Control Director, King Abdul Aziz Specialist Hospital – Taif, Saudi Arabia, and published many International articles on prevention of central line –associated bloodstream infection, WHO- Hand Hygiene implementation program, prevention sharp injuries in healthcare settings and molecular genotyping for epidemiological purposes and also participated in the Poster and oral presentations in many international conferences

Abstract:

Infection prevention and control programs involves everyone; the patient, healthcare workers, and visitors. In order to maintain a health and safe environment, any effective strategy must understand that you are dealing with people with different languages, religions, nationalities and cultural attitudes. Therefore, preventionists should have an effective ability to communicate new skills, and to encourage and motivate people involved. Plus, an ability to address issues and flawed implementation habits that have formed historically within the organization.

Based on my local experience in Taif, Saudi Arabia, organizations should believe  strongly in their value systems and in their appropriate standards in the clinical environment. These rules should become not just guidelines but “organizational law”. Zero tolerance of healthcare associated infections can be achievable for MOH hospitals by following the SHEA/IDSA practice guidelines and setting them as applicable standards or “laws”. For example, we observed 60% reduction of central-line associated bloodstream infection and achieved to NHSN 50 percentile of catheter associated urinary tract infections in 2012. Also, there is increasing evidence, that international or national accreditation programs can play a vital role in healthcare service improvement. Infection control auditing compliance rate results in hospital standards on infection control have increased from 76% to 86% during 2017

OMICS International Infection Prevention 2017 International Conference Keynote Speaker Lbachir BenMohamed  photo
Biography:

Dr. BenMohamed is a Professor of Immunology, the founder and the head of the Laboratory of Cellular and Molecular Immunology in the Department of Ophthalmology at the University of California. He also holds a joint appointment with the Center of Immunology at UC Irvine and with Chao Family Comprehensive Cancer Center UCI Medical center. Dr. BenMohamed received his Ph.D. in Immunology from the Pasteur Institute, Paris, France in 1997 where he worked as the key developer and co-inventor of a new promising vaccine strategy that uses mucosal delivery of clinically approved lipopeptide molecules. Dr. BenMohamed has been involved in clinical immunology, humoral and cellular immune responses, epitope mapping, epitope improvement, and the development and optimization of sub-unit vaccines against several infectious diseases including malaria Plasmodium falciparum, human immunodeficiency virus (HIV), human cytomegalovirus (HCMV) and herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2). Dr. BenMohamed is an independent immunologist, with a national and international reputation in vaccine development against both infectious diseases and cancer. Dr. BenMohamed is well integrated into the scientific community within the United States as well as Europe and is actively involved in a number of professional societies including American Association of Immunologists (AAI), American Society for Microbiology (ASM), American Society for Hematology (ASH), Association for Research in Vision and Ophthalmology (ARVO).

Abstract:

Herpes simplex virus type 1 (HSV-1) is a prevalent human pathogen that infects over 3.72 billion individuals worldwide and can cause potentially blinding recurrent corneal herpetic disease. HSV-1 establishes latency within sensory neurons of trigeminal ganglia (TG) and TG-resident CD8+ T cells play a critical role in preventing its reactivation. The repertoire, phenotype and function of protective CD8+ T cells are unknown. Bolstering the apparent feeble numbers of CD8+ T cells in TG remains a challenge for immunotherapeutic strategies. In this study, a comprehensive panel of 467 HLA-A*0201-restricted CD8+ T cell epitopes were predicted from the entire HSV-1 genome. CD8+ T cell responses to these genome-wide epitopes were compared in HSV-1 seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent herpetic disease) vs. asymptomatic (ASYMP) individuals (who are infected but never experienced any recurrent herpetic disease). Frequent polyfunctional HSV-specific effector memory IFN-+CD107a/b+CD44highCD62LlowCD8+ TEM cells were detected in ASYMP individuals and were mainly directed against three “ASYMP” epitopes. In contrast, SYMP individuals have more mono-functional central memory CD44highCD62LhighCD8+ TCM cells. Furthermore, therapeutic immunization with an innovative prime/pull vaccine, based on priming with multiple “ASYMP” epitopes (prime) and neurotropic TG delivery of the T-cell attracting chemokine CXCL-10 (pull), boosted the number and function of CD44highCD62LlowCD8+ TEM and tissue-resident CD103highCD8+ TRM cells in TG of latently infected HLA-A*0201 Tg mice and reduced recurrent ocular herpes following UV-B induced reactivation. These findings have profound implications in the development of T-cell-based immunotherapeutic strategies to treat blinding recurrent herpes infection and disease.

Footnotes: This work is supported by Public Health Service Research R01 Grants EY026103, EY019896 and EY024618 from National Eye Institute (NEI) and R21 Grant AI110902 from National Institutes of allergy and Infectious Diseases (NIAID), by The Discovery Center for Eye Research (DCER) and by a Research to Prevent Blindness (RPB) grant.